Docoh
Loading...

TLIS Talis Biomedical

Talis is dedicated to transforming diagnostic testing by developing and commercializing innovative products that are designed to enable accurate, low cost and rapid molecular testing for infectious diseases at the point-of-care, beginning with COVID-19. The company is developing Talis One, a compact, sample-to-answer, cloud-enabled, molecular diagnostic platform. Talis is headquartered in Menlo Park, California.

TLIS stock data

(
)

Investment data

Data from SEC filings
Securities sold
Number of investors

Calendar

10 Aug 21
18 Oct 21
31 Dec 21
Quarter (USD)
Jun 21 Mar 21 Dec 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
Dec 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Cash burn rate (estimated) Burn method: Change in cash Burn method: Operating income/loss Burn method: FCF (opex + capex)
Cash on hand (at last report) 348.88M 348.88M 348.88M
Cash burn (monthly) 11.52M 21.45M 87K
Cash used (since last report) 41.64M 77.56M 314.51K
Cash remaining 307.24M 271.32M 348.56M
Runway (months of cash) 26.7 12.6 4006.4

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
2 Oct 21 Robert J. Kelley Stock Option Common Stock Grant Acquire A No No 6.17 130,000 802.1K 427,202
2 Oct 21 Douglas Liu Stock Option Common Stock Grant Acquire A No No 6.17 200,000 1.23M 514,685
2 Oct 21 John Roger Moody Jr Stock Option Common Stock Grant Acquire A No No 6.17 130,000 802.1K 579,897
30 Aug 21 Popovits Kimberly J Stock Option Common Stock Grant Acquire A No No 9.06 550,000 4.98M 550,000
13 Aug 21 Ramesh Ramakrishnan Common Stock Sell Dispose S No No 7.66 27,502 210.67K 38,619
13 Aug 21 Ramesh Ramakrishnan Common Stock Option exercise Acquire M No No 1.5 8,741 13.11K 66,121
13 Aug 21 Ramesh Ramakrishnan Common Stock Option exercise Acquire M No No 1.5 43,614 65.42K 57,380
13 Aug 21 Ramesh Ramakrishnan Stock Option Common Stock Option exercise Dispose M No No 1.5 8,741 13.11K 0
13 Aug 21 Ramesh Ramakrishnan Stock Option Common Stock Option exercise Dispose M No No 1.5 43,614 65.42K 0

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

76.2% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 43 44 -2.3%
Opened positions 6 44 -86.4%
Closed positions 7 0 NEW
Increased positions 13 0 NEW
Reduced positions 17 0 NEW
13F shares
Current Prev Q Change
Total value 183.9M 268.82M -31.6%
Total shares 19.58M 20.92M -6.4%
Total puts 0 0
Total calls 0 0
Total put/call ratio
Largest owners
Shares Value Change
Baker Bros. Advisors 7.57M $83.55M 0.0%
ArrowMark Colorado 5.87M $32.69M -2.2%
Boxer Capital 1.55M $17.11M 0.0%
Nicholas Investment Partners 1.07M $11.82M -2.7%
BLK Blackrock 807.3K $8.9M +11.8%
Vanguard 544.91K $6.01M +39.7%
MS Morgan Stanley 442.25K $4.88M +2458.6%
Redmile 363.85K $4.01M -9.0%
Geode Capital Management 258.04K $2.85M +11.2%
STT State Street 205.93K $2.27M +40.0%
Largest transactions
Shares Bought/sold Change
FHI Federated Hermes 15K -1.02M -98.5%
MS Morgan Stanley 442.25K +424.97K +2458.6%
Sectoral Asset Management 0 -405.09K EXIT
Perceptive Advisors 0 -250K EXIT
Pictet Asset Management 33.85K -171.5K -83.5%
Vanguard 544.91K +154.89K +39.7%
ArrowMark Colorado 5.87M -130.05K -2.2%
JPM JPMorgan Chase & Co. 42.23K -116.45K -73.4%
BLK Blackrock 807.3K +84.89K +11.8%
STT State Street 205.93K +58.86K +40.0%

Financial report summary

?
Risks
  • Risks related to our business and strategy
  • Risks related to regulatory matters
  • Risks related to our intellectual property
  • Risks related to our financial condition and capital requirements
  • Risks related to ownership of our common stock
Management Discussion
  • Our revenue for the three months ended June 30, 2021 and 2020 relates to the CARB-X and NIH grants and the RADx initiative. During the three months ended June 30, 2021, $0.1 million of revenue was recognized related to our NIH grant. During the three months ended June 30, 2020, $0.3 million, $0.2 million, and $0.3 million of revenue was recognized related the NIH, CARB-X grants, and RADx grants, respectively.
  • Substantially all of our research and development expenses incurred for the three months ended June 30, 2021 were related to the manufacturing scale-up for, and development of our first potential commercial product utilizing the Talis One system, a rapid, point-of-care molecular diagnostic test to detect COVID-19 directly from a patient sample.
  • Research and development expenses were $54.5 million for the three months ended June 30, 2021, compared to $8.2 million for the three months ended June 30, 2020, an increase of $46.3 million. The increase was primarily due to increases of $23.0 million related to the automation of consumable manufacturing, an increase of $10.6 million in instrument component costs, an increase of $7.1 million relating to Talis One cartridge materials for the COVID-19 assay, including $3.6 million related to the modification of one of the agreements with our suppliers, and an increase of $2.4 million related to professional and personnel related expenses, including increased consulting expenses, stock compensation expenses, and personnel related expenses as we increased full-time and temporary headcount, and an increase of $3.2 million relating to an increase in outside services, allocated facilities and IT costs, supplies, freight and logistics costs.
Content analysis
?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. senior Avg

Proxies

No filings